Vinay Puduvalli
M.D. Anderson Cancer Center · Ohio State University: James Cancer Center · Brain Tumor Trials Collaborative (BTTC), and Ohio State University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Vinay Puduvalli as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05879120 · Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent GlioblastomaM.D. Anderson Cancer Center · withdrawn · Recurrent Glioblastoma · principal investigator
- Ph2NCT02337686 · Pembrolizumab in Treating Patients With Recurrent GlioblastomaM.D. Anderson Cancer Center · active not recruiting · Recurrent Glioblastoma, Recurrent Gliosarcoma · principal investigator
- Ph1NCT02197169 · DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain TumorsDNAtrix, Inc. · completed · Glioblastoma or Gliosarcoma · principal investigator
- Ph1NCT01430351 · Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation TherapyM.D. Anderson Cancer Center · terminated · Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma · principal investigator
- Ph1/Ph2NCT00555399 · Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)M.D. Anderson Cancer Center · terminated · Glioblastoma Multiforme, Anaplastic Glioma · study chair
- Ph1NCT00102648 · Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with TemozolomideM.D. Anderson Cancer Center · unknown · Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Neuroscience ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2026 · $170,449 awarded in 2026Same name and institution; not confirmed by an ID
- A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with GlioblastomaR01CA235673 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2024 · $541,645 awarded in 2024Same name and institution; not confirmed by an ID
- Patient Oriented Research Program in Neuro-oncologyK24CA160777 · NCI · OHIO STATE UNIVERSITY · fiscal years 2012 to 2015 · $72,326 awarded in 2015Same name and institution; not confirmed by an ID
- Efficacy and toxicity of TRAIL against gliomasR01CA114422 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2006 to 2010 · $181,692 awarded in 2010Same name and institution; not confirmed by an ID
- Correlative trial of fenretinide against GlioblastomasR21CA097767 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2002 to 2003 · $279,463 awarded in 2003Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:55 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.J Clin Oncol · 2010408 citationsRCR 10.1
- Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.Clin Cancer Res · 2006319 citationsRCR 7.0
- Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med · 2023275 citationsRCR 24.2
- Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.J Clin Oncol · 2002188 citationsRCR 4.1
- Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.J Neurooncol · 200889 citationsRCR 2.0
- Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.J Clin Oncol · 200480 citationsRCR 1.6
- A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.J Neurooncol · 201667 citationsRCR 2.2
- 66 citationsRCR 2.1
- A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.J Neurooncol · 201657 citationsRCR 2.0
- Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.Clin Cancer Res · 201254 citationsRCR 1.4